Premium
Pioglitazone in acromegaly – an open‐label, prospective study
Author(s) -
Kim David D. W.,
Goh Jovina,
Panossian Zaven,
Gamble Greg,
Holdaway Ian,
Grey Andrew
Publication year - 2012
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2012.04411.x
Subject(s) - pioglitazone , acromegaly , medicine , endocrinology , prospective cohort study , diabetes mellitus , insulin resistance , type 2 diabetes , growth hormone , hormone
Summary Objective Preclinical studies demonstrate that thiazolidinediones ( TZD s) decrease growth hormone ( GH ) and insulin‐like growth factor‐1 ( IGF ‐1) levels, suggesting that they might be effective treatments for acromegaly. This study investigated the effect of pioglitazone on biochemical indices of disease activity in acromegaly. Design and participants This was a 4‐month open‐label prospective study in 16 patients with active acromegaly who were attending public hospital endocrinology clinics. Methods The intervention was pioglitazone 45 mg/day. The primary outcome was change in serum IGF ‐1; the secondary outcome was change in area under the curve of glucose‐suppressed GH . Results Serum IGF ‐1 did not change during treatment with pioglitazone ( P = 0·95). After 4 months, the mean (95% CI ) change from baseline was −1 μg/l (−51, 49). GH levels following oral glucose loading were unchanged during pioglitazone therapy. After 4 months, the mean (95% CI ) change from baseline in area under curve for glucose‐suppressed GH was 31 μg/l (−75, 138, P = 0·54). Conclusions Short‐term treatment with conventional doses of pioglitazone did not improve biochemical measures of disease activity in acromegaly.